

## **Dr Lin's Statement**

Dr. Shih-Ku Lin graduated from Kaohsiung Medical University in 1981 and completed his psychiatric residency at the Taipei City Psychiatric Center (TCPC). After attaining board certification in psychiatry, he pursued a fellowship in child psychiatry at the Kansas University Medical Center in 1988. In 1993, he was appointed Chief of the Department of Addiction Science at TCPC, a position he held for 11 years. He subsequently chaired the Department of Psychiatry at Taipei City Hospital and Psychiatric Center and served as an Adjunct Associate Professor at the Taipei Medical University College of Medicine.

Following his retirement from TCPC in July 2020, Dr. Lin relocated to Linkou Chang Gung Memorial Hospital. Throughout his career, he has collaborated closely with Professor Wen-Ho Chang in academic research. Their team has published numerous studies on the therapeutic drug monitoring of antipsychotics and has contributed significantly to the field of psychopharmacology regarding racial and ethnic differences between East Asian and Western populations.

Dr. Lin played a pivotal role in founding the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN), serving as its inaugural Secretary in 2002 and as President from 2016 to 2019. Additionally, Dr. Lin is a pioneer of addiction psychiatry in Taiwan; he founded the Taiwanese Society of Addiction Science and served as its first President in 2008. In this field, his research group investigates alcohol and heroin dependence, methamphetamine-induced psychosis, and ketamine use disorder, with work spanning from genetic studies to clinical interventions.

Dr. Lin's research interests center on psychopharmacology, with a specific focus on ethnic differences in pharmacokinetics and clinical trials for novel therapeutics. He currently serves as a coordinator alongside Professor Takahiro Kato (President elect of Asian Federation of Psychiatric Associations) within the Research on Asian psychotropic prescription pattern (REAP) consortium—the largest and longest-running international collaborative psychiatric research network in Asia. The participating countries including China, India, Indonesia, Japan, Iran, Korea, Malaysia, Pakistan, Singapore, Sri Lanka, Taiwan, and Thailand, with the honorary consultants Professors Norman Sartorius and Naotaka Shinfuku.

Dr. Lin's research interests center on psychopharmacology, with a specific focus on ethnic differences in pharmacokinetics and clinical trials for novel therapeutics. He currently serves as a coordinator alongside Professor Takahiro Kato (President-elect of the Asian Federation of Psychiatric Associations) within the Research on Asian Psychotropic Prescription Patterns (REAP) consortium—the largest and longest-running international collaborative psychiatric research network in Asia. Participating countries include China, India, Indonesia, Japan, Iran, Korea, Malaysia, Pakistan, Singapore, Sri Lanka, Taiwan, and Thailand, with Professors Norman Sartorius and Naotaka Shinfuku serving as honorary consultants. To date, this consortium has produced more than 110 papers published in both international and domestic peer-reviewed journals..

Dr. Lin also possesses more than twenty years of experience in Phase II and III global clinical trials for major pharmaceutical companies. He has published over 180 peer-reviewed papers and serves as a reviewer for numerous international journals.

### **International Experience & WPA Participation**

Dr. Lin's history with the World Psychiatric Association (WPA) began at the XII World Congress in 2002 in Yokohama, Japan—the first ever held in Asia. He subsequently attended the XIII World Congress in Cairo, Egypt (2005) and the XVI World Congress in Madrid, Spain (2014).

He was actively involved in the organizing committees for the 2011 WPA Regional Meeting in Kaohsiung and the 2015 WPA International Congress in Taipei, both of which were hosted by the Taiwanese Society of Psychiatry. During his tenure as Vice-President of the International College of Neuropsychopharmacology (CINP), and in response to the COVID-19 pandemic, Dr. Lin—together with the TSBPN—successfully hosted the 32nd CINP Congress (2021) as a virtual event and the 33rd CINP Congress (2022) in a hybrid format. The latter featured the central theme: "Neuropsychopharmacology in the Digital Era."